COGT vs TRMK Comparison

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Trustmark Corp is a bank holding company. Through its subsidiaries, the company operates as a financial services organization providing banking and other financial solutions in Alabama, Florida, Mississippi, Tennessee, and Texas. Its principal products and services include Commercial Banking, Consumer Banking, Mortgage Banking, Insurance, Wealth Management and Trust Services, and others. The company is managed along two operating segments: General Banking and Wealth Management. The General Banking segment, which generates the majority of the revenue, provides all traditional banking products and services, including loan deposits, and also consists of internal operations.